Carolyn Brokowski’s scholarly pioneering work in biomedical engineering and bioethics, focusing on emerging, novel nucleic-acid-editing technologies, is recognized and esteemed internationally. Her formal educational training and experience bring unique depth and breadth to her work. She studied biomedical science, philosophy, law, and engineering at graduate levels. Throughout the COVID-19 pandemic, she helped to facilitate and oversee human opioid and anti-COVID-pharmaceutical clinical research trials in every dimension of health care— ranging from pre-hospital settings to emergency departments to surgical intensive care units — at Yale New Haven Hospitals. For over a decade, Carolyn was an active voting member of Yale University’s Institutional Review Board. She is completing a PhD, funded by the Department of War (Defense), in biomedical engineering at the School of Mechanical, Aerospace, and Manufacturing Engineering at the University of Connecticut.